Gastroenterology Learning Network

Russell Cohen, MD, expert in IBD and new therapies, discusses the advantages of the subcutaneous formulation of vetilismab over the IV formulation, the effectiveness of Atrasimod for ulcerative colitis, and the introduction of Mira Kizumab as the first IL-23 inhibitor for ulcerative colitis.

Dr. Brian Lacy interviews Dr. Douglas Drossman on disorders of gut-brain interaction. They discuss the disruption in the brain-gut connection, prevalence and impact of these disorders, factors affecting gut-brain interaction, and the impact on patients and the healthcare system. They also explore healthcare costs, diagnosis, and concerns about cancer or inflammatory bowel disease.

Dr Raymond Cross quizzes Dr Frank Farraye on the latest guidance regarding vaccinations against COVID-19 and RSV in this episode of IBD DriveTime.

Dr. Linda Nguyen and Dr. Brian Lacy discuss the updated guideline on diagnosing and managing gastroparesis. They cover accurate diagnosis, personalized therapy including concerns about metoclopramide, use of prokinetic agents, and the importance of personalized care for treating gastroparesis.

Guest Michael Dolinger, MD, from the Icahn School of Medicine at Mount Sinai, talk to host Millie Long, MD, about the use and advantages of intestinal ultrasound for monitoring inflammatory bowel disease.

In this episode of IBD Drive Time, guest host David Rubin, MD, calls on Drs Severine Vermeire of KU Leuven University in Belgium and Dan Tucker of Hebrew University of Jerusalem to talk about the challenges of recruiting patients for clinical trials in inflammatory bowel disease and the ethical issues involved.

Dr Scott discusses the development of a pathway based on specific diagnostic criteria that indicate the need to refer patients with inflammatory bowel disease to specialist centers.

In the latest IBD Drive Time, host Raymond Cross, MD, talks with Ryan Stidham, MD, about potential applications for artificial intelligence and ChatGPT in gastroenterology practice—and what is feasible right now.

Dr Mark Pimentel, an expert in small intestinal bacterial overgrowth and intestinal methanogen overgrowth (IMO), provides an update on diagnosing and treating SIBO. The podcast covers the symptoms and diagnostic challenges of SIBO and IMO, the controversy surrounding gut microbiota testing, measuring hydrogen sulfide in breath tests, and the relationship between SIBO and IBS.

The podcast discusses the effectiveness of Upadacitinib therapy for Crohn's disease, highlighting its superior alternative to placebo. They review the trial results, efficacy, tolerability, and safety of the drug. The speakers also discuss treatment approaches for active IBD and spondyloarthropathy, as well as the potential benefits of jack inhibitors for pydderma. They touch on clinical trial results, dosing considerations, and conclude that the benefits of Upadacitinib outweigh the risks.